Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M73,043Revenue $M6,494Net Margin (%)22.3Z-Score5.7
Enterprise Value $M73,765EPS $1.7Operating Margin %27.9F-Score7
P/E(ttm))53.1Cash Flow Per Share $4.4Pre-tax Margin (%)25.7Higher ROA y-yN
Price/Book15.410-y EBITDA Growth Rate %0Quick Ratio5.2Cash flow > EarningsY
Price/Sales11.05-y EBITDA Growth Rate %22.2Current Ratio5.4Lower Leverage y-yN
Price/Cash Flow17.9y-y EBITDA Growth Rate %2.8ROA % (ttm)10.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)25.9Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M801ROI % (ttm)17.8Gross Margin Increase y-yY

Gurus Latest Trades with CELG

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CELGGeorge Soros 2014-06-30 Buy 0.45%$68.45 - $86.8
($75.89)
$ 91.3620%New holding, 688000 sh.688,000
CELGJoel Greenblatt 2014-06-30 Buy 0.07%$68.45 - $86.8
($75.89)
$ 91.3620%New holding, 63980 sh.63,980
CELGRonald Muhlenkamp 2014-06-30 Reduce-1.91%$68.45 - $86.8
($75.89)
$ 91.3620%Reduce -51.74%144,140
CELGRay Dalio 2014-06-30 Sold Out -0.08%$68.45 - $86.8
($75.89)
$ 91.3620%Sold Out0
CELGJohn Burbank 2014-06-30 Sold Out -0.01%$68.45 - $86.8
($75.89)
$ 91.3620%Sold Out0
CELGRay Dalio 2014-03-31 Add0.07%$69.65 - $85.97
($79.51)
$ 91.3615%Add 962.69%142,400
CELGJohn Burbank 2014-03-31 Buy 0.01%$69.65 - $85.97
($79.51)
$ 91.3615%New holding, 1670 sh.3,340
CELGJohn Keeley 2014-03-31 Sold Out $69.65 - $85.97
($79.51)
$ 91.3615%Sold Out0
CELGRonald Muhlenkamp 2013-12-31 Add0.12%$72.25 - $85.39
($79.05)
$ 91.3616%Add 2.87%294,850
CELGRay Dalio 2013-12-31 Buy 0.01%$72.25 - $85.39
($79.05)
$ 91.3616%New holding, 6700 sh.13,400
CELGMario Gabelli 2013-09-30 Add$60.13 - $77.31
($70.14)
$ 91.3630%Add 29.5%20,940
CELGJohn Keeley 2013-09-30 Buy $60.13 - $77.31
($70.14)
$ 91.3630%New holding, 1320 sh.2,640
CELGJohn Hussman 2013-09-30 Sold Out -0.31%$60.13 - $77.31
($70.14)
$ 91.3630%Sold Out0
CELGRonald Muhlenkamp 2013-06-30 Reduce-0.96%$56.1 - $65.09
($60.18)
$ 91.3652%Reduce -21.92%285,770
CELGJoel Greenblatt 2013-06-30 Sold Out -0.01%$56.1 - $65.09
($60.18)
$ 91.3652%Sold Out0
CELGJohn Hussman 2013-03-31 Reduce-0.71%$39.24 - $57.96
($50.79)
$ 91.3680%Reduce -85.25%118,000
CELGJoel Greenblatt 2013-03-31 Reduce-0.17%$39.24 - $57.96
($50.79)
$ 91.3680%Reduce -94.2%4,660
CELGRay Dalio 2013-03-31 Sold Out -0.07%$39.24 - $57.96
($50.79)
$ 91.3680%Sold Out0
CELGJoel Greenblatt 2012-12-31 Add0.16%$35.65 - $41.04
($38.7)
$ 91.36136%Add 989.15%80,314
CELGMario Gabelli 2012-12-31 Add$35.65 - $41.04
($38.7)
$ 91.36136%Add 68.37%17,510
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CELG is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CELG George Soros 2014-06-30688,0000.090.45New Buy
CELG Joel Greenblatt 2014-06-3063,9800.010.07New Buy
CELG Mario Gabelli 2014-06-3023,12000.01+7.34%
CELG Ronald Muhlenkamp 2014-06-30144,1400.022.2-51.74%
CELG Ray Dalio 2014-06-30000Sold Out
CELG John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


CELG: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CASEY MICHAEL DDirector 2014-08-14Sell30,000$88.593.07view
KARSEN PERRY Asee remarks 2014-08-04Sell39,104$87.554.29view
BARKER RICHARD WDirector 2014-07-25Sell17,600$87.034.92view
Celgene International Inc10% Owner 2014-07-08Buy200,000$10813.1view
KAPLAN GILLADirector 2014-06-09Sell30,000$80.8112.99view
CELGENE CORP /DE/10% Owner 2014-05-05Buy1,100,000$42.86113.04view
KARSEN PERRY Asee remarks 2014-05-01Sell23,844$73.3924.42view
Celgene European Investment Co10% Owner 2014-04-29Buy294,800$44107.52view
CELGENE CORP /DE/10% Owner 2014-04-14Buy714,286$71204.43view
CASEY MICHAEL DDirector 2014-03-04Sell25,540$81.1712.49view

Press Releases about CELG :

    Quarterly/Annual Reports about CELG:

    News about CELG:

    Articles On GuruFocus.com
    Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
    David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Trying to Beat the Market Is a Fool’s Errand Oct 17 2013 
    Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
    comment on CELG Mar 20 2013 
    Growth Stocks: There Is a Lot of Value in this Market Part 2 Sep 27 2012 
    High frowth cheap in Jun 30 2012 
    52-Week High Companies: CVS, TSM, PM, ROST, CELG Feb 27 2012 
    52-Week High Companies: CELG, MON, ECL, SBUX, NWSA Jan 16 2012 

    More From Our Partners
    Stock Market News for August 14, 2014 - Market News Aug 14 2014 - ZACKS

    More From Other Websites
    Jazz, Celgene Lead Top 4 Drugmaker Profit Margins Aug 18 2014
    [video] Cramer: Market about Russia-Ukraine Aug 18 2014
    [video] Companies that innovate get bids: Cramer Aug 14 2014
    [video] Amgen's cancer drug fails to improve survival rates Aug 14 2014
    Trade-Ideas: Celgene (CELG) Is Today's Momo Momentum Stock Aug 13 2014
    Drugs Stocks On The Rise With Help From 3 Stocks Aug 08 2014
    Mylan Misses Q2 Earnings and Sales Estimates, Adjusts View Aug 07 2014
    Why Investors Should Closely Watch Celgene Aug 06 2014
    Celgene: Five Reasons to Be Bullish Aug 06 2014
    Health Canada Approves ABRAXANE® Plus Gemcitabine for First-Line Treatment of Patients with... Aug 06 2014
    ClearBridge Value: Making It A Top Mutual Fund Again Aug 05 2014
    CELGENE CORP /DE/ Financials Aug 05 2014
    Amgen Cancer Drug Kyprolis Succeeds In Trial Aug 04 2014
    Pharmacyclics Q2 Earnings Get Mixed Reception Aug 01 2014
    Charles R. Kummeth, the President and CEO of Bio-Techne (TECH), Interviews with The Wall Street... Aug 01 2014
    United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat Jul 31 2014
    Celgene (CELG) On Momo Momentum Watch Today Jul 30 2014
    CELGENE CORP /DE/ Files SEC form 10-Q, Quarterly Report Jul 29 2014
    [video] Cummins 'a bad sign,' tech next: Cramer Jul 28 2014
    Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales Jul 25 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide